BIOMAT Database Logo BIOMAT Database Logo

Severe secondary hyperparathyroidism: intravenous calcitriol treatment or parathyroidectomy? 1996

M Goicoechea Diezhandino, and R Pérez-Garcia, and J M López-Gómez, and R Jofre, and F Valderrábano

UI MeSH Term Description Entries
D006962 Hyperparathyroidism, Secondary Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY. Secondary Hyperparathyroidism,Hyperparathyroidisms, Secondary,Secondary Hyperparathyroidisms
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016105 Parathyroidectomy Excision of one or more of the parathyroid glands. Parathyroidectomies

Related Publications

M Goicoechea Diezhandino, and R Pérez-Garcia, and J M López-Gómez, and R Jofre, and F Valderrábano
High doses of intravenous calcitriol in the treatment of severe secondary hyperparathyroidism.
January 2004, Journal of nephrology,
M Goicoechea Diezhandino, and R Pérez-Garcia, and J M López-Gómez, and R Jofre, and F Valderrábano
[The effectiveness of long-term treatment of severe secondary hyperparathyroidism with intravenous calcitriol].
September 1999, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
M Goicoechea Diezhandino, and R Pérez-Garcia, and J M López-Gómez, and R Jofre, and F Valderrábano
Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
August 2009, Nephrology (Carlton, Vic.),
M Goicoechea Diezhandino, and R Pérez-Garcia, and J M López-Gómez, and R Jofre, and F Valderrábano
Effectiveness of intravenous and subcutaneous calcitriol in the treatment of secondary hyperparathyroidism.
September 1998, Nephron,
M Goicoechea Diezhandino, and R Pérez-Garcia, and J M López-Gómez, and R Jofre, and F Valderrábano
Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol.
November 1992, Kidney international,
M Goicoechea Diezhandino, and R Pérez-Garcia, and J M López-Gómez, and R Jofre, and F Valderrábano
Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
January 1994, Mineral and electrolyte metabolism,
M Goicoechea Diezhandino, and R Pérez-Garcia, and J M López-Gómez, and R Jofre, and F Valderrábano
Beneficial role of intravenous calcitriol on bone mineral density in children with severe secondary hyperparathyroidism.
January 2004, International urology and nephrology,
M Goicoechea Diezhandino, and R Pérez-Garcia, and J M López-Gómez, and R Jofre, and F Valderrábano
Treatment for secondary hyperparathyroidism focusing on parathyroidectomy.
January 2023, Frontiers in endocrinology,
M Goicoechea Diezhandino, and R Pérez-Garcia, and J M López-Gómez, and R Jofre, and F Valderrábano
[Parathyroidectomy in secondary hyperparathyroidism].
March 1985, Minerva medica,
M Goicoechea Diezhandino, and R Pérez-Garcia, and J M López-Gómez, and R Jofre, and F Valderrábano
Parathyroidectomy for secondary hyperparathyroidism.
January 1974, The Mount Sinai journal of medicine, New York,
Copied contents to your clipboard!